BioDrugs
Abbreviated title (ISO 4) | BioDrugs |
---|---|
Discipline | Drug therapy, pharmacology |
Language | English |
Edited by | Kathy Fraser |
Publication details | |
Publisher | |
Publication history | 1994-present |
Frequency | 6/year |
Hybrid | |
2.867 | |
Indexing | |
ISSN |
1173-8804 (print) 1179-190X (web) |
CODEN | BIDRF4 |
Links | |
BioDrugs is a peer-reviewed pharmacology journal.
It has an impact factor of 2.867.[1]
It is published by Adis International (Springer Science + Business Media)
BioDrugs aims to advance discussion and evaluation of the latest developments in the clinical application of biotechnology for the treatment of human disease by providing a programme of review articles and original research covering the most important aspects of biotechnology-based pharmaceuticals, diagnostic products and innovations in bio-tech therapy.
This includes innovative therapeutic and diagnostic products; novel drug delivery systems; protein/peptide therapeutics; monoclonal antibodies and antibody fragments; cytokines and cytokine receptors; recombinant DNA and gene regulation technology; gene therapy; nucleic acid therapeutics and diagnostics; stem cell therapies; drug target validation; glycolated and pegylated therapeutics; and pioneering technologies in drug design and development. .
BioDrugs publishes articles on all areas of medicine.
Abstracted/Indexed in:- PubMed/Medline, Science Citation Index Expanded (SciSearch), Journal Citation Reports/Science Edition, SCOPUS, EMBASE, Chemical Abstracts Service (CAS), Google Scholar, EBSCO, CSA, CAB International, Academic OneFile, Academic Search, ASFA, BIOSIS, BIOSIS Review Reports and Meetings, CAB Abstracts, CSA Environmental Sciences, Current Contents/Clinical Medicine, Expanded Academic, Global Health, Health Reference Center Academic, Journals@OVID, OCLC, SCImago, Summon by ProQuest.